Hyphens Pharma expands brand portfolio with hair-loss products

HYPHENS Pharma on Monday said that it has procured all rights, titles and interests in the trademarks of hair-loss products CG 210 and CG4S from Legacy Healthcare (Switzerland) for Singapore and Malaysia, paving the way for it to sell and distribute the CG 210 product series and the CG4S shampoo in the two countries.  

The pharmaceutical and consumer healthcare group said that skin health is  a focus area for Hyphens, and that the latest additions complement its other brands such as Ceradan and TDF Derma Formula in its "proprietary brands" segment by adding scalp care to its dermatology portfolio. CG 210 is a patented topical botanical hair growth‐promoting agent. Its safety and efficacy have been demonstrated in more than 10 clinical studies involving close to 800 subjects, and written about in several publications, the company said. It added that to date, over two million units have been sold worldwide.

The products will contribute to the revenue and profitability of the group, although there will not be a material effect on the net tangible assets or earnings per share for the financial year ending Dec 31, 2020, it said.